Genmab (GMXAY) announced that worldwide net sales of DARZALEX as reported by Johnson & Johnson (JNJ) were $629M in the first quarter. Net sales were $352M in the U.S. and $277M in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.